Business

Eli Lilly Global CEO Meets Dr Jitendra; Discusses Insulin, NCD Drugs Collaboration

Eli Lilly’s Global CEO, David Ricks, shared the company’s plans during a meeting with Union Minister of State for Science and Technology Jitendra Singh. The discussions highlighted strategies to expand clinical trials, boost biomanufacturing capabilities, and enhance collaboration on diabetes management solutions in India.

• By Newsdesk
• New Delhi
• Mar 26, 2025

Business

Global pharmaceutical leader Eli Lilly is set to enhance access to insulin and expand its focus on non-communicable disease (NCD) therapies in India. Following the recent launch of its breakthrough anti-obesity drug Mounjaro (tirzepatide) in the country, the company is intensifying efforts to address the growing burden of diabetes and obesity.

Eli Lilly’s Global CEO, David Ricks, shared the company’s plans during a meeting with Union Minister of State for Science and Technology Jitendra Singh. The discussions highlighted strategies to expand clinical trials, boost biomanufacturing capabilities, and enhance collaboration on diabetes management solutions in India.

Tackling India’s Diabetes Challenge

India currently faces a diabetes epidemic, with over 101 million people living with the condition. Singh underscored the significance of developing treatments tailored to the country’s unique metabolic profiles.

“There is a notable difference in metabolic disorders in India compared to the rest of the world, largely due to dietary habits and genetic factors leading to central and visceral obesity,” Singh said, emphasizing the importance of region-specific research.

Eli Lilly’s expansion aligns with India’s Atmanirbhar Bharat initiative, which promotes domestic pharmaceutical manufacturing to reduce dependency on imports. The company’s focus on biomanufacturing will not only bolster local production but also enhance the availability of critical medicines.

Strengthening Partnerships for Greater Access

Eli Lilly has already established a robust presence in India through its subsidiary, Eli Lilly and Company (India) Pvt. Ltd., which provides medications for diabetes, gastric and lung cancers, breast cancer, osteoporosis, and rheumatoid arthritis. Additionally, the company operates in neighboring countries, including Nepal, Bangladesh, and Sri Lanka, via strategic partnerships.

In line with its commitment to affordable and accessible healthcare, Eli Lilly formed a partnership with Cipla in 2021 to expand the reach of diabetes drugs like Humalog and Trulicity across India. Furthermore, the company has collaborated with Gland Pharma for the local manufacturing of human insulin vials, ensuring stable supply chains and reducing costs.

Expanding the Reach of Mounjaro

Eli Lilly’s latest innovation, Mounjaro (tirzepatide), which targets both type 2 diabetes and obesity, received regulatory approval in India in March 2025. Its introduction is expected to revolutionize diabetes management, providing patients with an effective solution for weight and blood sugar control.

As part of its broader growth strategy, Eli Lilly plans to launch Mounjaro in other emerging markets, including Brazil and Mexico, further expanding its global footprint.

A Collaborative Approach to Healthcare

The meeting between Ricks and Singh reflects the growing collaboration between multinational pharmaceutical firms and the Indian government to improve healthcare outcomes. Singh highlighted the importance of integrating advanced therapies with generic medicines to ensure accessibility without compromising innovation.

Eli Lilly’s operations in India include Eli Lilly and Company (India) Pvt. Ltd., established in 1993, focusing on product development and marketing. The company also operates Eli Lilly Services India Pvt. Ltd. in Bengaluru, which supports global research and scientific advancements.

Through its strategic initiatives, Eli Lilly is not only contributing to diabetes management in India but also reinforcing the country’s position as a leading player in global pharmaceutical manufacturing and research.